A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label, noncomparative study to evaluate safety,efficacy
and of single-agent EZN 2208 administered in patients with previously treated MBC.
After discontinuation of study treatment, patients will receive care as considered
appropriate by the investigator. Patients will continue to be followed for disease
progression, subsequent anticancer therapy, and survival.